Australia markets open in 3 hours 10 minutes

Medlab Clinical Limited (MDC.AX)

ASX - ASX Delayed price. Currency in AUD
Add to watchlist
0.0590+0.0050 (+9.26%)
At close: 04:10PM AEST
Full screen
Previous close0.0540
Open0.0570
Bid0.0580 x 3519200
Ask0.0590 x 165200
Day's range0.0570 - 0.0610
52-week range0.0430 - 0.2000
Volume313,312
Avg. volume415,504
Market cap20.188M
Beta (5Y monthly)1.11
PE ratio (TTM)N/A
EPS (TTM)-0.0310
Earnings date29 Aug 2022 - 02 Sept 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est0.42
  • GlobeNewswire

    Medlab (ASX:MDC) receives Government grant to apply NanoCelle® to an RNA nasal vaccine in collaboration with University of NSW (UNSW) and Macquarie University (MQ) to fight COVID-19 future potential epidemics

    NSW Government grant received on 23rd December 2021 to develop a “no-jab” vaccine solutionMedlab collaborates with UNSW and MQ University (two leading global academic and R&D institutions)This NanoCelle® non-invasive nasal delivered vaccine is considered a “first in class” medicine delivery systemThis Government Grant & Academic collaboration solidify Medlab’s transition to a true Biotech company.Global relevance expectation is extremely highNanoCelle® as an asset is yet to be valued in any anal

  • GlobeNewswire

    Nanocelle® Patent Granted in Usa

    Medlab receives Granted Patent Protection for NanoCelle® in the USA by US Patent & Trademark Office (USPTO) SYDNEY, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Medlab Clinical Ltd (ASX: MDC) is extremely pleased to announce the USPTO has granted patent protection for NanoCelle® “Transmucosal and transdermal delivery systems” (Patent No. 11160753) in the United States of America. This announcement follows just three weeks after announcing the ‘Notice of Allowance’ received by the USPTO. (October 06, 2021).

  • GlobeNewswire

    DEPRESSION PATENT FOR OROTATE APPROVED & GRANTED BY US PATENT OFFICE

    SYDNEY, Oct. 11, 2021 (GLOBE NEWSWIRE) -- Medlab Clinical LTD (ASX:MDC) is pleased to announce the Orotate patent, specifically to addressing depression in United States of America has been granted. The United States Patent and Trademark Office (USPTO) has applied a Patent term to 28 MAY 2037 with a US patent number 11,135,181. Previously Medlab announced [5 Jul 2021] final trial readouts for its phase 2 Depression trials.Orotate use as a drug substance was key to the investigative product “NRGB